Elesesterpenes A–K: Lupane-type Triterpenoids From the Leaves of Eleutherococcus sessiliflorus

Dong Han†, Yan Liu†, Xiao-Mao Li, Si-Yi Wang, Yan Sun, Adnan Mohammed Algradi, Hai-Dan Zou, Juan Pan, Wei Guan, Hai-Xue Kuang* and Bing-You Yang*

Key Laboratory of Basic and Application Research of Beiyao, Ministry of Education, Heilongjiang University of Chinese Medicine, Harbin, China

Elesesterpenes A–K (1–11), eleven new lupane-type triterpenoids, triterpenoid glycosides, and nortriterpenoid were isolated from the leaves of Eleutherococcus sessiliflorus. Their structures and relative configurations were completely elucidated by a combination of diverse methods including physical, spectroscopic data. The absolute configuration of elesesterpenes A–B (1–2) was defined by single-crystal X-ray diffraction. Meanwhile, all the isolates were evaluated for anti-inflammatory activities on lipopolysaccharide-induced nitric oxide production in BV2 microglial cells, and antiproliferative activities against human hepatoma (HepG2), human lung adenocarcinoma (A549), and human glioma cells (LN229) in vitro. It was found that some of them exhibited obvious anti-inflammatory activities and potent antiproliferative activities.

Keywords: Eleutherococcus sessiliflorus, triterpenoids, nortriterpenoid, triterpenoid glycosides, antiproliferative, anti-inflammatory

INTRODUCTION

Triterpenoids, a kind of structural diversity secondary metabolites in the plant kingdom, are derived from the cyclization of squalene through different pathways and are widely distributed in various plants (Salvador et al., 2012; Thimmappa et al., 2014). Most triterpenoids are tetracyclic or pentacyclic triterpenes; pentacyclic triterpenes can be roughly divided into four subtypes, including oleanane, ursane, lupane, and friedelane. E. sessiliflorus is widely distributed in Northeast China. It is a type of folk herbal medicine which helps in nourishing liver and kidney, strengthening body and bones, and is used for treating cerebrovascular diseases, tumors, rheumatism, and arthralgia (Jung et al., 2005; Lee et al., 2012). Abundant secondary metabolites, mainly flavonoids and triterpenoids, have been isolated from E. sessiliflorus (Yoshizumi et al., 2006; Zhang et al., 2019). Among them, 3,4-seco-lupane–type triterpenoids are characteristic chemical constituents, which exhibit many pharmacological activities, such as antiproliferative, antidepressant, and hepatoprotective activities (Bian et al., 2017; Bian et al., 2018).

In the current study, we describe six triterpenoids, four triterpenoid glycosides, and one nortriterpenoid (Figure 1) from the leaves of E. sessiliflorus, including their isolation, structural elucidation, the anti-inflammatory activity on BV2 cells, and antiproliferative activities on HepG2, A549, and LN229 cell lines.

EXPERIMENTAL SECTION

General Experimental Procedures

HR-ESI-MS spectra were selected on a Thermo Scientific Orbitrap Fusion™ Lumos™ Tribrid™ mass spectrometer (Thermo, America). GC-MS analysis was performed on an Agilent 7890A system with...
a DB-1701 (30 m × 0.25 mm, 0.25 μm) capillary column (Agilent Technologies, America). NMR spectra were collected by a Bruker DPX-600 spectrometer (1H: 600 MHz, 13C: 150 MHz) with the tetramethylsilane as an internal standard and pyridine-d₅ (Cambridge Isotope Laboratories Inc., America) as deuterated reagents. The melting point was determined on a melting point apparatus (XPF-550C, CK-300, Shanghai Caikon Optical Instrument Co., Ltd. China). Preparative HPLC was performed with a Shimadzu Shim-pack GIST C18 column (20 × 250 mm, 5 μm), equipped with RID-20A detector, and LC20AR HPLC pump flow rates were 5 ml/min (Shimadzu Corporation, Japan). Optical rotations were measured using a Jasco P-2000 digital polarimeter. X-ray crystallographic data were measured by Bruker D8 Venture. Column chromatography was carried out using silica gel (80–100 mesh and 200–300 mesh, Qingdao Marine Chemical Inc., China) and ODS (50 μm, YMC Company Ltd., Japan). Thin-layer chromatography was conducted with GF254 (Qingdao Marine Chemical Inc., China), which was observed with a UV lamp (254 and 366 nm) and heated after spritzing with 10% H₂SO₄ in alcohol, and 10% H₂SO₄-EtOH reagent was sprayed and heated at 130°C for 5 min to detect spots.

Plant Material

The leaves of *E. sessiliflorus* were collected from Dandong, Liaoning Province of China in August 2020, and identified by

![Graphical Abstract](image-url)
Prof. Rui-Feng Fan of Heilongjiang University of Chinese Medicine. The voucher specimen (No. 20200821) was deposited at Heilongjiang University of Chinese Medicine.

**Extraction and Isolation**

The dried leaves of *E. sessiliflorus* (30 kg) were extracted under reflux with EtOH-H2O (2 h × 3 times, 70:30, v/v). The crude extracts were eluted by HP-20 macroporous resin with EtOH-H2O (0:100, 40:60, 95:5, v/v), yielding 0% EtOH-H2O (1.4 kg), 40% EtOH-H2O (1.1 kg), and 95% EtOH-H2O (0.4 kg) elution fractions.

The 95% EtOH-H2O elution fractions (0.4 kg) were subjected to gel column with 200–300 mesh, eluted with the solvent system CH2Cl2-CH3OH (100:0, 80:1, 50:1, 30:1, 20:1, 15:1, 10:1, 5:1, 2:1, 1:2, 1:100, v/v) yielding nine fractions (Fr. A–Fr. I). Based on TLC analysis, Fr. D (10.0 g) was separated by ODS, and forty-five subfractions were obtained. Fr. D-16 was further separated with preparative HPLC to afford 8 (2.8 mg) and 10 (12.5 mg). Fr. D-18 was purified by preparative HPLC to afford 6 (7.4 mg), 7 (9.8 mg), and 9 (5.57 mg). Fr. D-24 was submitted by preparative HPLC to afford 1 (18.5 mg) and 2 (5.5 mg). Fr. H (99.3 g) was separated by ODS, and forty-two subfractions were obtained. Fr. H-19 was further purified by preparative HPLC to afford 11 (27.4 mg). Fr. H-29 was separated by preparative HPLC to afford 3 (13.6 mg). Fr. H-32 was purified by preparative HPLC to afford 4 (15.4 mg) and 5 (17.3 mg).

**Hydrolysis of Compounds 3, 4, 5, and 11**

Each compound (1.0 mg) was hydrolyzed in 2 ml (2 mol/L) of HCl and incubated in water bath at 80°C for 4 h. The mixture was concentrated under vacuum, and the resulting residue was suspended in water and extracted with ethyl acetate (3 × 2.0 ml). And the aqueous layer was evaporated dry under reduced pressure. The residue was dissolved in dry pyridine (1 ml) with L-cysteine methyl ester hydrochloride (2 ml, 0.1 mol/L) and shaken at 60°C for 1 h. Subsequently, N-trimethylsilylimidazole was added and heated at 60°C for 1 h. The reaction mixture was suspended in 1.0 ml H2O and extracted with n-hexane (3 × 1.0 ml). The layer of n-hexane was collected. Flavonol subfractions were obtained. Fr. D-16 was further separated with preparative HPLC to afford 8 (2.8 mg) and 10 (12.5 mg). Fr. D-18 was purified by preparative HPLC to afford 6 (7.4 mg), 7 (9.8 mg), and 9 (5.57 mg). Fr. D-24 was submitted by preparative HPLC to afford 1 (18.5 mg) and 2 (5.5 mg). Fr. H (99.3 g) was separated by ODS, and forty-two subfractions were obtained. Fr. H-19 was further purified by preparative HPLC to afford 11 (27.4 mg). Fr. H-29 was separated by preparative HPLC to afford 3 (13.6 mg). Fr. H-32 was purified by preparative HPLC to afford 4 (15.4 mg) and 5 (17.3 mg).

**Cytotoxic Assay**

TV2 microglial cells, HepG2, and LN229 cells were incubated in high-glucose DMEM with 10% heat-inactivated FBS, containing 1% antibiotic (penicillin-streptomycin) at 37°C in 5% CO2. Additionally, A549 cells were cultured in F12 (10% FBS, 100 IU/ml penicillin, and 100 μg/ml streptomycin) (Ko et al., 2016).

Three human cancer cell lines (HepG2, A549, and LN229) were incubated at 2 × 10^5 cells/mL in a 96-well microplate for 12 h. Each tumor cell line was exposed to the test compounds at various concentrations (0, 20, 40, 60, 80, and 100 μM) for 24 h. Then the cells were tested with 0.5 mg/ml CCK-8 and incubated for 2 h at 37°C in 5% CO2.

TV2 microglial cells were cultured in a 96-well microplate, which was treated with 1 μg/ml LPS for 12 h. Then, they were treated with different concentrations of the compounds 1–11 (0, 20, 40, 60, 80, and 100 μM) for 12 h for the detection of nitric oxide (NO) content in the supernatant of cell culture medium. After the Griess reaction, they were incubated for 0.5 h at 37°C in 5% CO2. The absorbance of cells was determined at 490 nm by a microplate reader.

**X-Ray Crystallographic Analysis**

Crystallographic data of 1 and 2 were collected on a Bruker D8 ventura diffractometer employing Ga Ka radiation. The structures were refined with full-matrix calculations using SHELX 2018/3 (Sheldrick, 2015). Deposition numbers CCDC 2111722 and 2114935 could be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Eleuthereseone A (1): C30H46O6, M = 502.67, T = 173 K, V = 2648.7 (11), Dcalc = 1.261 g/cm³, Z = 4, tetragonal, p43, a = 9.1862 (16) Å, b = 9.1862 (16) Å, c = 31.388 (7) Å, α = β = γ = 90°, F (000) = 1.096, GOF = 1.041, 4.187° ≤ θ ≤ 60.632°, -11 ≤ h ≤ 10, -11 ≤ k ≤ 11, -33 ≤ l ≤ 39, data/restraints/parameters 5370/1/334, final R indices R1 = 0.077 (wR2 = 0.1835) [I > 2σ (I)] for 5370 independent reflections [Rint = 0.1090], R indices (all data) R1 = 0.1561 (wR2 = 0.2241) for reflections were collected. Flack parameter: 0.0 (4). The deposited number CCDC of 1 was 2111722.

Eleuthereseone B (2): C30H46O6, C22H14N, M = 563.75, T = 173 K, V = 1485.8 (2), Dcalc = 1.260 g/cm³, Z = 2, monoclinic, p1211, a = 13.6515 (10) Å, b = 6.7760 (6) Å, c = 17.1284 (14) Å, α = γ = 90°, β = 110.325 (4)°, F (000) = 612, GOF = 1.069, 2.393° ≤ θ ≤ 60.133°, -15 ≤ h ≤ 17, -8 ≤ k ≤ 5, -19 ≤ l ≤ 21, data/restraints/parameters 5453/1/377, final R indices R1 = 0.0427 (wR2 = 0.0970) [I > 2σ (I)] for 5453 independent reflections [Rint = 0.0476], R indices (all data) R1 = 0.0601 (wR2 = 0.1061) for reflections were collected. Flack parameter: 0.0 (2). The deposited number CCDC of 2 was 2114935.

**RESULTS AND DISCUSSION**

Structure Elucidation of Compounds

Eleuthereseone A (1) was isolated as a white acicular crystal. It had a molecular formula of C30H46O6, as established by positive high-resolution-electrospray ionization–mass spectrometry (HR-ESI-MS) ion peak at m/z 503.3360 ([M + H] +, calculated for C30H46O6, 503.3373). The 1H-NMR spectrum of 1 (Table 1) showed the characteristic signals of six methyl signals [δH 1.45 (3H, s, H2-23), 1.36 (3H, s, H2-24), 1.47 (3H, s, H2-25), 1.11 (3H, s, H2-26), 1.08 (3H, s, H2-27), and 1.74 (3H, s, H2-29)] and two terminal alkene protons [δH 4.65 (H, s, H-30a) and 4.86 (H, s, H-30b)]. Combined with the 13C-NMR, DEPT, and HSQC spectra analyses, six methyl carbons [δC 29.6 (C-23), 27.8 (C-24), 14.1 (C-25), 17.4 (C-26), 14.4 (C-27), and 19.6 (C-29)], a pair of olefinic...
TABLE 1 | $^1$H (600 MHz) and $^{13}$C NMR (150 MHz) data in pyridine-$d_5$ for 1-2 and 6-7.

| No | $^1$H (δ in ppm, J in Hz) | $^{13}$C (δ in ppm) |
|----|------------------------|--------------------|
| 1  | 79.2 (br d, 7.1, 12.5) | 147.7 (C-20)       |
| 2  | 84.9 (dd, 12.5, 17.5) | 150.7 (C-20)       |
| 3  | 215.0 (br d, 12.1)    | 172.9 (C-20)       |
| 4  | 52.0 (br d, 12.1)     | 41.5 (C-20)        |
| 5  | 21.0 (br d, 12.1)     | 2.00 (C-20)        |
| 6  | 1.96 (m)              | 2.00 (C-20)        |
| 7  | 32.2 (br d, 12.1)     | 1.56 (C-20)        |
| 8  | 39.9 (br d, 12.1)     | 4.03 (C-20)        |
| 9  | 56.4 (br d, 12.1)     | 4.03 (C-20)        |
| 10 | 40.3 (br d, 12.1)     | 4.03 (C-20)        |
| 11 | 77.8 (br d, 12.1)     | 4.03 (C-20)        |
| 12 | 34.0 (br d, 12.1)     | 4.03 (C-20)        |
| 13 | 39.6 (br d, 12.1)     | 4.03 (C-20)        |
| 14 | 42.8 (br d, 12.1)     | 4.03 (C-20)        |
| 15 | 31.4 (br d, 12.1)     | 4.03 (C-20)        |
| 16 | 32.2 (br d, 12.1)     | 4.03 (C-20)        |
| 17 | 56.4 (br d, 12.1)     | 4.03 (C-20)        |
| 18 | 49.5 (br d, 12.1)     | 4.03 (C-20)        |
| 19 | 47.7 (br d, 12.1)     | 4.03 (C-20)        |
| 20 | 151.2 (br d, 12.1)    | 4.03 (C-20)        |
| 21 | 31.0 (br d, 12.1)     | 4.03 (C-20)        |
| 22 | 31.6 (br d, 12.1)     | 4.03 (C-20)        |
| 23 | 25.2 (br d, 12.1)     | 4.03 (C-20)        |
| 24 | 66.0 (br d, 12.1)     | 4.03 (C-20)        |
| 25 | 11.8 (br d, 12.1)     | 4.03 (C-20)        |
| 26 | 16.1 (br d, 12.1)     | 4.03 (C-20)        |
| 27 | 15.8 (br d, 12.1)     | 4.03 (C-20)        |
| 28 | 178.9 (br d, 12.1)    | 4.03 (C-20)        |
| 29 | 19.7 (br d, 12.1)     | 4.03 (C-20)        |
| 30 | 109.8 (br d, 12.1)    | 4.03 (C-20)        |

carbon [δC 150.7 (C-20) and 110.0 (C-30)], two oxygenated tertiary carbons [δC 79.2 (C-1) and 69.6 (C-11)], two carboxyl carbons [δC 172.9 (C-3) and 178.8 (C-28)] were assigned. The $^1$H-$^1$H COSY correlations (Figure 2) showed the main fragment of the triterpenoid framework based on the cross-peaks H-9/H-11/H-12/H-13/H-18/H-19/H-21/H-22. In addition, three other fragments (H-1/H-2; H-5/H-6/H-7; and H-15/H-16) are shown in Figure 2. The HMBC correlations (Figure 2) of H-23, H-24/C-4; H-1, H-2/C-3 combined with the above NMR signals indicated that 1 could be a triterpenoid with 3,4-lactone. The HMBC correlations of H2-30/C-19, C-29; H-18/C-20 defined the Δ20 (30) terminal double bond as a part of the C-20 isopropenyl moiety. Thus, the 2D structure of 1 was similar to that of viburolide, which was reported from Viburnum aboricolum, except for the presence of two hydroxy groups at C-1 (δC 79.2) and C-11 (δC 69.6) in 1 rather than a hydroxy group at C-6 in viburolide (Ku et al., 2003). The relative configuration of 1 was determined by the analysis of the NOESY experiment (Figure 3). Based on biosynthesis principles, H-26 was tentatively assigned β-orientation and H-27 was assigned α-orientation as in lupane-type triterpenoids. The correlations of H-1/H-5/H-9/H-11/H-27; H-11/H-36 were observed. Therefore, it was inferred that H-1 and H-11 were α-orientation and β-orientation, respectively. Furthermore, the X-ray crystal structure (Figure 4) of 1 was obtained by crystallization from MeOH at 24°C [Ga Kα radiation, Flack parameter = 0.0 (4), CCDC 2111722], which unambiguously determined the absolute configuration of 1 as 1R, 5R, 8R, 9S, 10R, 11R, 13R, 14R, 17S, 18R, 19R. Elesesterpene B (2) was obtained as a white acicular crystal. HR-ESI-MS showed a molecular ion at m/z 485.3260 ([M + H] $^+$), calculated for C30H45O5 485.3267, which agreed with the molecular
based on the analysis of the NMR data of \(2\) (Table 1), five methyl carbons, one carbonyl carbon, one carboxyl carbon, a set of double bonds, one oxygenated secondary carbon, and two oxygenated tertiary carbons could be inferred. The \(^1\)H-\(^1\)H COSY correlations of \(2\) revealed the existence of four fragments identical with that of \(1\) (Figure 2). The six-membered ring A was distinct from 1, which was determined by the key HMBC correlations of \(H_2-2/C-1, C-3; H_3-23/C-4, C-5, \) and \(C-24; H_2-24/ C-3\) (Figure 2). Therefore, the planar structure of \(2\) was established as shown in Figure 1. The absence of correlation between C-1
The molecular formula of C$_{50}$H$_{80}$O$_{19}$ as deduced from HR-ESI-MS ion at m/z 986.5679 ([M + NH$_4$]$^+$, calculated for C$_{50}$H$_{84}$NO$_{18}$, 986.5688). Through comparison of the $^1$H and $^{13}$C NMR data between 5 and 4, it was obvious that the methyl ester at C-3 was replaced by an ethyl ester ($\delta_{C}$ 60.3 and 14.3); this judgment was confirmed by several correlations of H$_{2}$-1$''''$/H$_{3}$-2$''''$, H$_{2}$-1$''''$/C-3 in the $^1$H-$^1$H COSY and HMBC (Figure 2). The relative configuration of 5 was entirely consistent with that of 4 (Figure 6).

Elesesterpene E (5) was also purified as a yellow amorphous solid. Its molecular formula was determined to be C$_{50}$H$_{80}$O$_{19}$ by the HR-ESI-MS ion at m/z 986.5679 ([M + NH$_4$]$^+$, calculated for C$_{50}$H$_{84}$NO$_{18}$, 986.5688). Through comparison of the $^1$H and $^{13}$C NMR data between 5 and 4, it was obvious that the methyl ester at C-3 was replaced by an ethyl ester ($\delta_{C}$ 60.3 and 14.3); this judgment was confirmed by several correlations of H$_{2}$-1$''''$/H$_{3}$-2$''''$, H$_{2}$-1$''''$/C-3 in the $^1$H-$^1$H COSY and HMBC (Figure 2). The relative configuration of 5 was entirely consistent with that of 4 (Figure 6).

Elesesterpene F (6) was obtained as a colorless amorphous solid with a molecular formula of C$_{39}$H$_{44}$O$_{19}$ based on the HR-ESI-MS ion at m/z 517.3179 ([M + H]$^+$, calculated for C$_{39}$H$_{45}$O$_{17}$, 517.3165). The $^1$H-NMR and $^{13}$C-NMR data of 6 were similar to those of chiisanogenin obtained previously from Acanthopanax divaricatus, and the only change was that the $\Delta^20$ (30) double bond was replaced by a carboxyl group (Lee et al., 2003). It was supported by correlations of H-20, H$_3$-29/C-30 in HMBC (Figure 2). NOESY correlations (Figure 3) between H-1/H-25; H-5/H-9/H$_3$-27 were observed. Therefore, H-1 and H-5 were inferred as $\beta$- and $\beta$-orientation, respectively.

Elesesterpene G (7), a yellow amorphous solid, was determined to be C$_{29}$H$_{44}$O$_{20}$ by HR-ESI-MS at m/z 487.3074 ([M + H]$^+$, calculated for 487.3060). Comparison of the $^1$H and $^{13}$C NMR data (Table 1) of 7 with the data of 6 showed the
| No | δC (J in Hz) | δH (J in Hz) |
|---|---|---|
| 1 | 37.4 | 1.96 (overlap) |
| | | 3.04 (td, 5.9, 13.1) |
| 2 | 30.2 | 2.59 (m) |
| | | 3.13 (m) |
| 3 | 174.9 | — |
| 4 | 148.3 | — |
| 5 | 51.2 | 2.16 (m) |
| | | 2.00 (dd, 2.6, 12.5) |
| 6 | 25.1 | 1.31 (m) |
| | | 1.27 (m) |
| 7 | 33.7 | 1.23 (overlap) |
| | | 1.32 (overlap) |
| 8 | 42.3 | — |
| 9 | 45.7 | 1.92 (d, 10.7) |
| | | 1.55 (m) |
| 10 | 40.0 | — |
| 11 | 69.6 | 4.15 (m) |
| 12 | 37.8 | 1.61 (m) |
| | | 2.33 (dt, 4.1, 12.8) |
| 13 | 37.2 | 2.87 (dddt, 3.5, 10.3, 12.8) |
| 14 | 42.9 | — |
| 15 | 30.1 | 1.23 (overlap) |
| | | 1.20 (overlap) |
| 16 | 32.1 | 1.52 (dt, 3.2, 13.0) |
| | | 1.50 (overlap) |
| 17 | 56.9 | — |
| 18 | 49.3 | 1.80 (overlap) |
| 19 | 47.1 | 3.39 (dt, 5.0, 11.0) |
| | | 3.37 (dt, 5.0, 10.9) |
| 20 | 150.3 | — |
| 21 | 30.8 | 1.40 (m) |
| | | 1.42 (m) |
| 22 | 36.6 | 1.47 (m) |
| | | 2.20 (m) |
| 23 | 113.9 | 4.88 (br s) |
| | | 4.96 (br s) |
| 24 | 23.7 | 1.80 (s) |
| 25 | 20.8 | 1.19 (s) |
| 26 | 17.9 | 1.20 (s) |
| 27 | 14.7 | 1.11 (s) |
| 28 | 174.8 | — |
| 29 | 19.4 | 1.66 (s) |
| 30 | 110.2 | 4.60 (br s) |
| | | 4.79 (br s) |
| 1° | 95.2 | 6.32 (d, 8.2) |
| 2° | 74.0 | 4.09 (m) |
| 3° | 78.6 | 4.21 (t, 9.4) |
| 4° | 70.8 | 4.30 (t, 9.4) |
| 5° | 77.9 | 4.09 (m) |
| 6° | 69.3 | 4.27 (dd, 4.9, 11.6) |
| | | 4.28 (dd, 4.7, 11.3) |
| 13° | 105.0 | 4.94 (d, 7.7) |
| 23° | 75.2 | 3.92 (t, 7.7) |
| 33° | 76.4 | 4.12 (m) |
| 43° | 78.1 | 4.40 (t, 9.3) |
| 53° | 77.1 | 5.64 (dt, 3.1, 9.3) |
| 63° | 61.2 | 4.07 (m) |
| 1°* | 102.6 | 5.85 (br s) |
| 2°* | 72.5 | 4.67 (overlap) |
| 3°* | 72.7 | 4.54 (dd, 3.3, 9.2) |
| 4°* | 73.9 | 4.33 (m) |
| 5°* | 70.2 | 4.93 (overlap) |
| 6°* | 18.4 | 1.69 (d, 6.2) |
| 1°*** | 59.8 | 4.09 (m) |
| 2°*** | 14.3 | 1.06 (t, 7.1) |
| 1H (600 MHz) and 13C NMR (150 MHz) data in pyridine-d5 for 3-5.
close similarity between the structures, except for the existence of a ketone carbonyl signal at $\delta_C$ 211.1. The $^{13}$C NMR and DEPT spectra of 7 resolved 29 carbon signals; these suggested that 7 was a nortriterpenoid. Further analysis of the correlations (H-18, H$_3$-29/C-20) established that the ketone carbonyl was straightforwardly assigned to C-19. The relative configuration of 7 was entirely consistent with that of 6 (Figure 3).

Elesesterpene H (8) was obtained as a yellow amorphous solid. The molecular formula of the compound was C$_{31}$H$_{48}$O$_7$ as established by HR-ESI-MS data [(M + H)$^+$, 533.3467; calculated for C$_{31}$H$_{49}$O$_7$, 533.3478]. The $^1$H-NMR and $^{13}$C-NMR data (Table 3) of 8 were similar to those of acanthosessilioside C obtained from the fruits of Acanthopanax sessiliflorus, and it was found to lack a sugar moiety at the C-28 position by contrast (Lee et al., 2012). The correlation of H-1/C-4 in the HMBC (Figure 2) suggested that C-1 and C-4 were connected by an oxygen bridge. Furthermore, the coupling constant between H-22 and H$_2$-21 was 5.3 Hz, indicating that H-22 is $\beta$-orientation (Shirasuna et al., 1997). The NOESY correlations of H-1/H-11/H$_3$-25 (Figure 3) indicated that H-1 and H-11 were designated to be of $\beta$-orientation.

Elesesterpene I (9) was obtained as a yellow amorphous solid with a molecular formula of C$_{32}$H$_{50}$O$_7$ as determined by the HR-ESI-MS [(M + H)$^+$, 547.3627; calculated for C$_{32}$H$_{51}$O$_7$, 547.3627]. The $^1$H and $^{13}$C-NMR data of 9 (Table 3) were closely related to those of 8. Through the $^1$H-$^1$H COSY correlation of H$_2$-1''''/H$_3$-2'''' and the HMBC correlation of H$_2$-1''''/C-3, it was determined that C-3 was connected to ethyl ester rather than methyl ester. The relative configurations of 9 were established to be the same as those of 8 by the NOESY experiment (Figure 3).

Elesesterpene J (10) was isolated as a white amorphous powder. Its molecular formula was determined as C$_{30}$H$_{48}$O$_6$ on the basis of HR-ESI-MS data [(M + H)$^+$, 503.3366; calculated for C$_{30}$H$_{47}$O$_6$, 503.3373]. Comparison of the NMR data (Tables 3) of 10 with the data of 8 showed the absence of a methoxy signal and a hydroxyl signal. The correctness of the inference was confirmed by the correlation signals of H-9/H$_2$-11/H$_2$-12 in $^1$H-$^1$H COSY spectra (Figure 2). As with compound 8, H-1 and H-22 were defined as $\beta$-orientation.

Elesesterpene K (11) was isolated as a yellow amorphous solid. The molecular formula of 11 was established to be C$_{30}$H$_{50}$O$_{20}$ on the basis of its HR-ESI-MS data at m/z 1001.5293 [(M + H)$^+$, calculated for C$_{30}$H$_{51}$O$_{20}$, 1001.5321]. The $^1$H and $^{13}$C-NMR data (Tables 3) were similar to those for 9, with the main difference being the absence of a hydroxyl group and the presence of three sugar units. Acid hydrolysis of 11 released D-glucose and L-rhamnose, which were identified by GC analysis after derivatization. The sugar moieties (δ$_C$ 95.2, 74.0, 78.5, 70.7, 77.9, 69.3; δ$_C$ 104.9, 75.2, 76.3, 78.1, 77.0, 61.2; δ$_C$ 102.6, 72.4, 72.6, 73.8, 70.2, 18.4) were assigned via comparison of the experimental and reported NMR data. The correlations of H-18, H$_2$-22/C-28 were observed from the HMBC spectrum. The correlation peaks of H-1/H$_2$-11/H$_3$-25 in the NOESY spectrum showed that H-1 and H-11 have uniform $\beta$-orientation in space.

**Bioactive Activity**

Finally, the antiproliferative activities of these compounds were evaluated against HepG2, A-549, and LN229. And most of the compounds showed significant inhibitory effects. Further analysis of the data showed that compounds 5, 7, 8, and 10 exhibited more extensive and potent effects with the IC$_{50}$ values ranging from 1.05 to 8.60 μM (Table 4).

The bioactivities of isolated metabolites were also evaluated for the anti-inflammatory assay in vitro. All of them exhibited different degrees of suppression on NO production in LPS-activated BV2 microglial cells (Table 4), and compound 3 was the best (IC$_{50}$ = 2.33 ± 0.31 μM).

**CONCLUSION**

E. sessiliflorus was a kind of medicinal and edible herbal medicine. Numerous new compounds were isolated from the leaves in our study, including ten triterpenoids (1–6 and 8–11) and one nortriterpenoid (7). These were worth mentioning; the C-30 of compounds 6 and 7 had a rare change from the double bond to carboxyl and ketone carbonyl groups, respectively; in compound 2, C-1 and C-11 were linked to form a rare five-membered oxygen ring. All of these changes were reported for the first time. In addition, compounds 3,
| No | 8  | 9  | 10 | 11 |
|----|----|----|----|----|
| 8  |     |     |     |     |
| 9  |     |     |     |     |
| 10 |     |     |     |     |
| 11 |     |     |     |     |

**Table 3** $^1$H (600 MHz) and $^{13}$C NMR (150 MHz) data in pyridine-d$_5$ for 8–11.
5, 9, and 11 all had an extra segment (-OCH2CH3) in C-3 compared with known triterpenoids. Thus, 3, 5, 9, and 11 were possible to be the artifacts. A possibility was proposed: some esterification reactions occurred during the refluxing extraction of ethanol. To further avoid the introduction of 3-OCH2CH3, a lot of methods are currently being carried out in our studies, and the results will be reported in due course.

### REFERENCES

Bian, X., Wang, S., Liu, J., Zhao, Y., Li, H., Zhang, L., et al. (2018). Hepatoprotective Effect of Chisanoside against Acetaminophen-Induced Acute Liver Injury in Mice. *Nat. Product. Res.* 33, 2704–2707. doi:10.1080/14786419.2018.1460841

Bian, X., Zhao, Y., Guo, X., Zhang, L., Li, P., Fu, T., et al. (2017). Chisanoside, a Triterpenoid Saponin, Exhibits Anti-tumor Activity by Promoting Apoptosis and Inhibiting Angiogenesis. *RSC Adv.* 7 (66), 41640–41650. doi:10.1039/C7RA08041G

Jung, H.-J., Nam, J. H., Choi, J., Lee, K.-T., and Park, H.-J. (2005). Anti-inflammatory Effects of Chisanoside and Chisanosinanogen Obtained from the Leaves of *Acanthopanax Chiisanensis* in the Carrageenan- and Freund’s Complete Adjuvant-Induced Rats. *J. Ethnopharmacology* 97, 359–367. doi:10.1016/j.jep.2004.11.026

Ko, W., Sohn, J. H., Jung, J. H., Ahn, I. S., Kang, D. G., Lee, H. S., et al. (2016). Inhibitory Effects of Alternaramide on Inflammatory Mediator Expression through TLR4-MyD88-Mediated Inhibition of NF-κB and MAPK Pathway Signaling in Lipopolysaccharide-Stimulated RAW264.7 and BV2 Cells. *Chemico-Biological Interactions* 244, 16–26. doi:10.1016/j.cbi.2015.11.024

Ku, Y.-L., Venkateswara Rao, G., Chen, C.-H., Wu, C., Guh, J.-H., and Lee, S.-S. (2003). A Novel Secobetulinic Acid 3,4-Lactone from *Viburnum Aboricium*. *Hua* 86 (3), 697–702. doi:10.1002/hilc.2003090068

Lee, D.-Y., Seo, K.-H., Lee, D.-S., Kim, Y.-C., Chung, I.-S., Kim, G.-W., et al. (2012). Bioactive 3,4-Seco-Triterpenoids from the Fruits of *Acanthopanax Senticosus*. *J. Nat. Prod.* 75, 1138–1144. doi:10.1021/np300217z

Lee, S., Shin, D.-S., Oh, K.-B., and Shin, K. H. (2003). Antibacterial Compounds from the Leaves of *Acanthopanax Senticosus*. *Arch. Pharm. Res.* 26 (1), 40–42. doi:10.1007/BF03179929

Park, S.-Y., Chang, S.-Y., Yook, C.-S., and Nohara, T. (2000). New 3,4-seco-lupane-type Triterpene Glycosides from *Acanthopanax Senticosus* Forma Inermis. *J. Nat. Prod.* 63 (12), 1630–1633. doi:10.1021/np000277c

Salvador, J. A. R., Moreira, V. M., Gonçalves, B. M. F., Leal, A. S., and Jing, Y. (2012). Ursane-type Pentacyclic Triterpenoids as Useful Platforms to Discover Anticancer Drugs. *Nat. Prod. Rep.* 29 (12), 1463–1479. doi:10.1039/c2np00608k

### DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

### AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

### FUNDING

This work was financially supported by the National Key Research and Development Project (2018YFC1707100), Heilongjiang Touyan Innovation Team Program, Heilongjiang University of Chinese Medicine funds (2018pt01 and 2018bs03).

### SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2021.813764/full#supplementary-material

---

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, or the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

---

**Copyright © 2022 Han, Liu, Li, Wang, Algradi, Zou, Pan, Kuang and Yang.** This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.